Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin- releasing hormone agonist  Bulent Ozcelik, M.D., Cagdas Turkyilmaz,

Slides:



Advertisements
Similar presentations
Effect of detorsion alone and in combination with enoxaparin therapy on ovarian reserve and serum antimüllerian hormone levels in a rat ovarian torsion.
Advertisements

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin- releasing hormone agonist  Bulent Ozcelik, M.D., Cagdas Turkyilmaz,
Age at menarche: a predictor of diminished ovarian function?
Akanksha Mehta, M.D., Mark Sigman, M.D.  Fertility and Sterility 
Cervical ripening before operative hysteroscopy in premenopausal women: a randomized, double-blind, placebo-controlled comparison of vaginal and oral.
Karl R. Hansen, M. D. , Ph. D. , George M. Hodnett, M. D
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.
Michael M. Alper, M.D.  Fertility and Sterility 
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials  Ana Cobo, Ph.D., César Diaz, M.D. 
Hepatitis and reproduction
Conservative management of cervical ectopic pregnancy
Cem Atabekoglu, M. D. , Murat Sonmezer, M. D. , Sinan Özkavukcu, M. D
Ethnicity as a determinant of ovarian reserve: differences in ovarian aging between Spanish and Indian women  Carlos Iglesias, M.D., Manish Banker, M.D.,
Medical treatment of ectopic pregnancy: a committee opinion
The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count  Simone L. Broer, B.Sc., Ben Willem J.
Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers  Andrea.
Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D
Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing.
How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization  Robert L. Klitzman, M.D.  Fertility.
A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data 
Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.
Oocyte cryopreservation
Do anti-mullerian hormone levels predict ovarian reserve in SLE patients presenting for hematopoietic stem cell transplant?  H. Browne, A. Armstrong,
Establishing a human chorionic gonadotropin cutoff to guide methotrexate treatment of ectopic pregnancy: a systematic review  Seema Menon, M.D., John.
Robert F. Casper, M.D.  Fertility and Sterility 
Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study  Ahmet Erdem, M.D., Mehmet Erdem,
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis  Laura P. Smith, M.D.,
Does stimulation with human gonadotropins and gonadotropin-releasing hormone agonist enhance and accelerate the developmental capacity of oocytes in human.
Tomer Singer, M. D. , David H. Barad, M. D. , M. S
Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility  Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,
Clomiphene citrate at 50: the dawning of assisted reproduction
Ovarian hyperstimulation secondary to ectopic secretion of follicle-stimulating hormone. Literature review prompted by a case  Jorge Burgos, M.D., Patricia.
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Introduction Fertility and Sterility
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Retrieval of immature oocytes after chemotherapy for Hodgkin's disease and prolonged ovarian down-regulation with gonadotropin-releasing hormone agonist 
Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,
Prospective cohort study of three- versus two-dimensional ultrasound for prediction of oocyte maturity  Doron Shmorgun, M.D., Edward Hughes, M.D., Patrick.
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
P-425 Fertility and Sterility Volume 86, Issue 3, (September 2006)
Effectiveness of highly purified human menopausal gonadotropin vs
Website quality assessment: Mistaking apples for oranges
Heterotopic autotransplantation of cryobanked human ovarian tissue as a strategy to restore ovarian function  S.Samuel Kim, M.D., In-Tak Hwang, M.D.,
L. Scott, J. Bernsten, K. DeLegge, J. Hill, N. Ramsing 
Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men  Subodhsingh Chauhan, M.D.,
Fertility and Sterility: an evaluation
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Sedigheh Borna, M.D., Azita Nasery, M.D.  Fertility and Sterility 
Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin.
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
Ovarian cystic teratoma with a pathognomonic appearance of multiple floating balls: a case report and investigation of common characteristics of the cases.
Current evaluation of amenorrhea
A woman with premature ovarian failure induced by Tripterygium wilfordii Hook.f. gives birth to a healthy child  Xin Chen, M.D., M.Sc., Shi-ling Chen,
Utilization of the Bologna criteria: a promise unfulfilled
Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation 
Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study  Ahmed Badawy, M.D., Aboubakr.
Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D
In vitro sildenafil citrate use as a sperm motility stimulant
Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development 
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
Presentation transcript:

Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin- releasing hormone agonist  Bulent Ozcelik, M.D., Cagdas Turkyilmaz, M.D., Mahmut Tuncay Ozgun, M.D., Ibrahim Serdar Serin, M.D., Cem Batukan, M.D., Saim Ozdamar, M.D., Ahmet Ozturk, M.D.  Fertility and Sterility  Volume 93, Issue 5, Pages 1609-1614 (March 2010) DOI: 10.1016/j.fertnstert.2009.02.054 Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Graphical description of mean and standard deviation of the follicle counts among groups. PMF = primordial follicle; PF = primary follicle; SF = secondary follicle; TF = tertiary follicle. Fertility and Sterility 2010 93, 1609-1614DOI: (10.1016/j.fertnstert.2009.02.054) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.